These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 10723590

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation.
    Mehta P, Beltz S, Kedar A, Graham-Pole J, Wingard JR.
    Bone Marrow Transplant; 1999 Dec; 24(12):1323-7. PubMed ID: 10627642
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
    Furlong T, Storb R, Anasetti C, Appelbaum FR, Deeg HJ, Doney K, Martin P, Sullivan K, Witherspoon R, Nash RA.
    Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
    [Abstract] [Full Text] [Related]

  • 6. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation.
    Yanik G, Levine JE, Ratanatharathorn V, Dunn R, Ferrara J, Hutchinson RJ.
    Bone Marrow Transplant; 2000 Jul; 26(2):161-7. PubMed ID: 10918426
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
    Hamazaki T, Yagi K, Inoue M, Sakata N, Okamura T, Yasui M, Sasabe M, Kishimoto T, Inoue A, Kawa K.
    Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106
    [Abstract] [Full Text] [Related]

  • 9. Differences between lymphocyte subsets, after allogeneic bone marrow transplantation, in patients who received tacrolimus and patients who received cyclosporin A.
    Fukuda H, Teshima H, Karasuno T, Hiraoka A, Nakamura H, Masaoka T.
    Int J Hematol; 2000 Jan; 71(1):70-4. PubMed ID: 10729997
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Acquired Pelger-Huët anomaly in association with concomitant tacrolimus and fluconazole therapy following allogeneic bone marrow transplantation.
    Gondo H, Okamura C, Osaki K, Shimoda K, Asano Y, Okamura T.
    Bone Marrow Transplant; 2000 Dec; 26(11):1255-7. PubMed ID: 11149744
    [Abstract] [Full Text] [Related]

  • 13. Acute pancreatitis due to tacrolimus in a case of allogeneic bone marrow transplantation.
    Sastry J, Young S, Shaw PJ.
    Bone Marrow Transplant; 2004 Apr; 33(8):867-8. PubMed ID: 14743193
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic study of the combination of tacrolimus and fluconazole in renal transplant patients.
    Lumlertgul D, Noppakun K, Rojanasthien N, Kanchanarattanakorn K, Jittikanont S, Manoyot A, Bunnachak D, Ophascharoensuk V.
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S73-8. PubMed ID: 17044457
    [Abstract] [Full Text] [Related]

  • 19. Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients.
    Trotter JF, Stolpman N, Wachs M, Bak T, Kugelmas M, Kam I, Everson GT.
    Liver Transpl; 2002 Mar; 8(3):212-8. PubMed ID: 11910565
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.